Hard To Treat Diseases (HTDS) to Retire Regulation D 50... (anagement to explore a possible lucrativ...)

Hard To Treat Diseases (HTDS) to Retire Regulation D 504 Offering

Date:9/3/2009

anagement to explore a possible lucrative joint venture project with a North American-based pharmaceutical company.

The issuer does not foresee the need or reason to disturb its current share structure, through dilution or otherwise. Management now intends to recalibrate its focus to its previously announced plans of addressing its share price, and matters that will increase its shareholder value. The issuer remains very optimistic that a 0.03 cent price per share is within its reach.

The issuer intends to furnish its shareholders with forward guidance shortly.

Safe Harbor Statement:

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund futu
'/>"/>

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Reportlinker Adds U.S. Markets for Addiction and Substance Abuse Treatment Report
2. Patients pretreatment quality of life can predict overall lung cancer survival
3. Twitter Users Can Follow in Real Time as Local Woman Receives Cyberknife Treatment for Lung Cancer
4. Forterus Inc. Treatment Centers Showing Consistent, Sustainable Growth; CEO Paul Howarth Interviewed
5. Potential Breakthrough Cancer Treatment Now Available From Vascular Designs
6. Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting
7. Two Treatments Equally Effective for Chronic Pelvic Pain
8. St. Lukes Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment
9. 2 Independent Studies Released on the Effectiveness of Prostate Cancer Treatment
10. National guideline released for the treatment of hoarseness
11. New treatment in sight for ovarian cancer

Post Your Comments:

(Date:12/16/2009)... (Nasdaq: BLUD ), a global leader in providing ... announced that Paul D. Mintz, M.D. has been appointed ... January 1, 2010. ,, Dr. Mintz has been ... than 30 years. He is a tenured Professor of ... of Medicine. He also serves as director of the ...

(Date:12/16/2009)... of C3: Colorectal Cancer Coalition,s advocacy efforts, $15 million ... included in the final Fiscal Year 2010 Defense Appropriations ... research cancers, like colorectal cancer, that are not addressed ... programs run by the U.S. Army Medical Research and ... funding for this new cancer research program was included ...

(Date:12/16/2009)... led by the Wellcome Trust Sanger Institute announce the ... cancers are caused by mutations in the DNA of ... The studies, of a malignant melanoma and a lung ... mutations in the genomes of two cancers. , Lung ... almost all are associated with smoking. The number of ...

(Date:12/16/2009)... to Quality, Cost-Effective Care , ... Washington, D.C. (Vocus) ... the best ways to rein in runaway costs while providing care ... part of the ongoing discussion includes how to ensure patients equal ... of medicine (MDs) or osteopathy (DOs). In both the House ...

(Date:12/16/2009)... MassBio promote Massachusetts companies through annual marketing campaign , ... ... -- BioSpace unveiled the 2010 Genetown™ Hotbed Campaign ... , , ,Genetown is sponsored by MassBio and ... industries. The campaign places each entity’s brand on an ...

Breaking Medicine News(10 mins):Health News:Immucor Appoints New Board Director 2 Health News:House Creates New Cancer Research Program 2 Health News:House Creates New Cancer Research Program 3 Health News:Lung cancer and melanoma laid bare 2 Health News:Lung cancer and melanoma laid bare 3 Health News:Lung cancer and melanoma laid bare 4 Health News:Lung cancer and melanoma laid bare 5 Health News:Lung cancer and melanoma laid bare 6 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5 Health News:Thriving Bioscience Region Leaves Its Mark 2

[1] Immucor Appoints New Board Director [0] House Creates New Cancer Research Program [1] Lung cancer and melanoma laid bare [1] Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs [0] Thriving Bioscience Region Leaves Its Mark

... neurological disorder in which misfiring electrical impulses in the ... epilepsy, and more than a million are female. //Pregnant ... that their children will have problems ranging from congenital ... to growing evidence that many commonly prescribed anti-epileptic drugs ...

... treatments may further increase the risk of breast and ... //Researchers offer new evidence that herbs such as red ... - as well as saw palmetto and rhodiola rosea ... could increase the risk of estrogen-related cancers. ...

... for long hours are more likely to be agitated.The ... and the New York State Psychiatric Institute. His team tracked ... found that those who had watched one or more hours ... into fights or behave aggressively towards other people later in ...

... According to a study, siblings of people with Alzheimer's ... of dementia.// More than half of patients with Alzheimer's ... This is an especially serious form of the condition, ... earlier need for institutional care. ,Researchers at ...

... Researchers say they've taken a major step toward cloning ... transplanted into humans. Such organs would save the lives ... transplants because of the shortage of human organs.// ... Dolly, scientists say they produced four piglets without one ...

... anxiety during pregnancy can increase a mother's risk of ... who were very anxious// in the last three months ... ,Lead researcher Professor Vivette Glover, of Imperial College, ... had extreme anxiety, and were frequently feeling scared.According ...

Other Medicine News:Health News: Pig cloning for organs, 2

Epilepsy Drugs Can Enhance Risk of Birth Defects Herbs With Estrogen Action Aggravate Cancer Risk Watching television for long hours could lead to agressiveness,Alzheimer's with psychosis runs in families Pig cloning for organs,Anxiety likely to affect the foetus

(Date:12/16/2009)... (Nasdaq: ARAY ), a global leader in the ... chief executive officer, Euan S. Thomson, Ph.D., is scheduled ... Conference in San Francisco on Wednesday, January 13, 2010 ... live webcast of each presentation will be available online ... site at http://www.accuray.com . The webcast replay ...

(Date:12/16/2009)... -- DATATRAK International, Inc. (OTCQX: DATA), a ... eClinical solutions for the clinical trials industry, ... 9.0 eClinical Software. This release advances ... service delivery and introduces two new mechanisms ... DATATRAK Learning Center(TM) and the DATATRAK Learning ...

(Date:12/16/2009)... Dec. 16 HealthWarehouse.com, Inc. (OTC Bulletin Board: ... had secured $1 million in 12% per annum short ... facility is an initial drawdown of $500,000, with accrued ... drawdown of $500,000 with accrued interest and principal repayable ... the Company becoming cashflow positive for any calendar month ...

Breaking Medicine Technology:Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference 2 DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 2 DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 3 DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 4 HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2 Dr Michael Barry of MGH is New President of Foundation for Informed Medical Decision Making 55396 1 Dr Michael Barry of MGH is New President of Foundation for Informed Medical Decision Making 55396 2 Dr Michael Barry of MGH is New President of Foundation for Informed Medical Decision Making 55396 3 Dr Michael Barry of MGH is New President of Foundation for Informed Medical Decision Making 55396 4 Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime Anywhere Access to Patient Data and Communications 55393 1 Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime Anywhere Access to Patient Data and Communications 55393 2 Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime Anywhere Access to Patient Data and Communications 55393 3 AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 1 AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 2 AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 3 AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 4 AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 5 AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 6 AED School Program at Its Best 3A Atlanta Public Schools Partnership With Cardiac Science 55390 7

[0] Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference [0] DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM)[0] HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing

... -- for Lung Cancer Diagnosis and, Identification of Tumor Origin in Patients With Cancer ... ... Types With High Sensitivity and, Specificity and Could Revolutionize Diagnosis and Treatment ... Accuracy Exceeding 90% and ...

... Novel Approach to Blood ... Pressure ... innovator in the discovery and development of novel small,molecule therapeutics, ... showed statistically significant,blood pressure reductions in a Phase 2a study ...

Other Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2 Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3 Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4 Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5 Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6 Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2 Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3 Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4 Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5 Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6 Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7 Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8

Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients

... knee prosthesis stems from many years of ... manufacturing technologies have been used in order ... as a favorable pressure distribution pattern on ... to a minimum. The inherent design of ...

... Knee design includes several innovative ... porous coating option for stable ... unique bone preserving posterior stabilizing ... to maximize range of motion, ...

Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...

Scorpio CR Knee is designed to address normal knee kinematics, range of motion (ROM) and polyethylene wear....

Medicine Products:

RT-PLUS Solution Natural-Knee Advance Posterior Stabilized Total Knee Systems Scorpio CR Knee, cruciate retaining single axis

Hard To Treat Diseases (HTDS) to Retire Regulation D 50...(anagement to explore a possible lucrativ...),Health